State of Wisconsin Investment Board Acquires Shares of 16,000 Spark Therapeutics, Inc. (ONCE)

State of Wisconsin Investment Board bought a new position in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 16,000 shares of the biotechnology company’s stock, valued at approximately $956,000. State of Wisconsin Investment Board owned about 0.05% of Spark Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Principal Financial Group Inc. raised its position in shares of Spark Therapeutics by 0.3% during the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after purchasing an additional 122 shares during the period. Nationwide Fund Advisors raised its position in shares of Spark Therapeutics by 2.5% during the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after purchasing an additional 414 shares during the period. KCG Holdings Inc. raised its position in shares of Spark Therapeutics by 9.4% during the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 538 shares during the period. Teachers Advisors LLC raised its position in shares of Spark Therapeutics by 1.9% during the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after purchasing an additional 650 shares during the period. Finally, American International Group Inc. raised its position in shares of Spark Therapeutics by 17.4% during the first quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock worth $618,000 after purchasing an additional 1,714 shares during the period. Hedge funds and other institutional investors own 91.01% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “State of Wisconsin Investment Board Acquires Shares of 16,000 Spark Therapeutics, Inc. (ONCE)” was originally published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/state-of-wisconsin-investment-board-invests-956000-in-spark-therapeutics-inc-once-stock/1599735.html.

Spark Therapeutics, Inc. (ONCE) opened at 81.27 on Friday. Spark Therapeutics, Inc. has a one year low of $35.07 and a one year high of $85.26. The firm’s market capitalization is $2.54 billion. The firm has a 50-day moving average price of $82.11 and a 200 day moving average price of $71.89.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. During the same period last year, the company earned ($1.04) EPS. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. Analysts anticipate that Spark Therapeutics, Inc. will post ($7.69) EPS for the current fiscal year.

A number of equities research analysts recently issued reports on the company. Jefferies Group LLC reissued a “buy” rating and issued a $95.00 target price (up previously from $85.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Evercore ISI assumed coverage on Spark Therapeutics in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $83.00 target price on the stock. Royal Bank Of Canada assumed coverage on Spark Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $100.00 target price on the stock. Zacks Investment Research raised Spark Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, Chardan Capital restated a “neutral” rating on shares of Spark Therapeutics in a research note on Monday, July 24th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and fifteen have issued a buy rating to the company. Spark Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $84.78.

In related news, insider Katherine A. High sold 10,000 shares of the stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the sale, the insider now directly owns 220,000 shares of the company’s stock, valued at approximately $13,200,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel Faga sold 6,000 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $82.50, for a total transaction of $495,000.00. Following the completion of the sale, the insider now directly owns 6,000 shares in the company, valued at $495,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 380,160 shares of company stock valued at $27,218,411. 7.30% of the stock is owned by insiders.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game


Leave a Reply

 
© 2006-2017 BBNS.